Oct 31 2020

Gene and Cell-Based Therapies for Parkinson's Disease: Where Are We?


Philip C Buttery, Roger A Barker
Author Affiliations
Abstract
Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics(United States)

Parkinson's disease (PD) is a neurodegenerative disorder that carries large health and socioeconomic burdens. Current therapies for PD are ultimately inadequate, both in terms of symptom control and in modification of disease progression. Deep brain stimulation and infusion therapies are the current mainstay for treatment of motor complications of advanced disease, but these have very significant drawbacks and offer no element of disease modification. In fact, there are currently no agents that are established to modify the course of the disease in clinical use for PD. Gene and cell therapies for PD are now being trialled in the clinic. These treatments are diverse and may have a range of niches in the management of PD. They hold great promise for improved treatment of symptoms as well as possibly slowing progression of the disease in the right patient group. Here, we review the current state of the art for these therapies and look to future strategies in this fast-moving field.

Keywords: Gene therapy, adeno-associated virus, embryonic, growth factor, lentivirus, pluripotent
Review, Journal Article
Neurotherapeutics

Suggested Articles

Nov 05 2020
Constipation and sleep behaviour disorder associate with processing speed and attention in males with Parkinson's disease over five years follow-up.
Scientific reports
Oct 31 2020
Dietary Antioxidants and the Mitochondrial Quality Control: Their Potential Roles in Parkinson's Disease Treatment.
Antioxidants (Basel, Switzerland)
Oct 29 2020
Variations in hospitalization rates across Parkinson's Foundation Centers of Excellence.
Parkinsonism & related disorders